Abstract
The clonogenic assay has been proposed both as a tool for individually guided chemotherapy and as a preclinical drug evaluation system. Because tumor cells are heterogeneous it is unlikely that a test where only a minor fraction of the cells is tested can predict the sensitivity of all tumor cells in the patient. The pronounced negative accuracy reported can be explained on the basis of the patient populations being studied. The technical limitations of the test are presented, and it is concluded that with the present status of the test, it is only suited as a preclinical test system.
It is suggested that in vitro sensitivity testing of drugs in a panel of cell lines established from patients with small cell carcinoma of the lung might help to identify drugs that could alter the clinical course of the disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Morstyn G, Ihde DC, Lichter AS, Bunn PA, Carney DN, Glatstein E, Minna JD: Small Cell Lung Cancer 1973–1983: Early progress and recent obstacles. Int J Radiat Oncol Biol Phys 10:515–539, 1984.
Hamburger AW: Use of in vitro tests in predictive cancer chemotherapy. J Natl Cancer Inst 66:981–988, 1981.
Roper PR, Drewinko B: Comparison of in vitro methods to determine drug-induced cell lethality. Cancer Res 36:2182–2188, 1976.
Puck TT, Marcus PI: Action of X-rays on mammalian cells. J Exp Med 103:653–666, 1956.
Salmon SE. Hamburger AW, Soehnlen B, Durie BGM, Alberts DS, Moon TE: Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med 298: 1321–1327, 1978.
Bertelsen CA, Sondak VK, Mann BD, Korn EL, Kern DH: Chemosensitivity testing of human solid tumors. Cancer 53:1240–1245, 1984.
Makuch RW: Interpreting clonogenic assay results. Lancet, ii: 438, 1982.
Vecchio TJ: Predictive value of a single diagnostic test in unselected populations. N Engl J Med 274:1171–1173, 1966.
Poste G, Greig R: The experimental and clinical implications of cellular heterogeneity in malignant tumors. J Cancer Res Clin Oncol 106:159–170, 1983.
Vindeløv L, Hansen HH, Spang-Thomsen M: Growth characteristics and heterogeneity of small cell carcinoma of the lung. In: Recent results in Cancer Research, Seeber, S (ed.), 97, pp 47–54. Springer-Verlag, Berlin, Heidelberg, 1985.
Talmadge JE, Benedict K, Madsen J, Fidler IJ: Development of biological diversity and susceptibility to chemotherapy in murine cancer metastases. Cancer Res 44:3801–3805, 1984.
Anonymous: Clonogenic assays for the chemotherapeutic sensitivity of human tumours. Lancet, i: 780–781, 1982.
Woodruff MFA: Cellular heterogeneity in tumours. Br J Cancer 47:589–594, 1983.
Selby P, Buick RN, Tannock I: A critical appraisal of the ‘human tumor stem-cell assay’. N Engl J Med 308:129–134, 1983.
Carney DN, Broder L, Edelstein M, Gazdar A, Hansen M, Havemann K, Matthews MJ, Sorenson GD, Vindeløv L: Experimental studies of the biology of human small cell lung cancer. Cancer Treat Rep 67:27–35, 1983.
Umbach G, Spitzer G, Drewinko B: ‘Clumpogenic’ v clonogenic assay. Lancet ii: 628, 1983.
Agrez MV, Kovach JS, Lieber MM: Cell aggregates in the soft agar ‘human tumour stem-cell assay’. Br J Cancer 46:880–887, 1982.
Engelholm SAa, Spang-Thomsen M, Brünner N, Nøhr I, Vindeløv LL: Disaggregation of human solid tumours by combined mechanical and enzymatic methods. Br J Cancer: 51:93–98, 1985.
Rasey JS, Nelson NJ: Response of an in vivo-in vitro tumour to X-rays and cytotoxic drugs: effect of tumour disaggregation method on cell survival. Br J Cancer 41/suppl 4:217–221, 1980.
Mann BD, Kern DH, Giuliano AE, Burk MW, Campbell MA, Kaiser LR, Morton DL: Clinical correlations with drug sensitivities in the clonogenic assay. Arch Surg 117:33–36, 1982.
Kaufmann M, Mattern J, Volm M, Hohorst HJ, Peter G, Voelcker G: In vitro testing of cyclophosphamide on tumors. Naturwissenschaften 62:446–447, 1975.
Shrivastav S, Stone KR, Paulson DF, Bonar RA: Activation of cyclophosphamide for in vitro testing of cell sensitivity. Cancer Res 40:4443–4445, 1980.
Fry JR, Bridges JW: A novel mixed hepatocyte-fibroblast culture system and its use as a test for metabolism-mediated cytotoxicity. Biochem Pharm 26:969–973, 1977.
Alberts DS, Salmon SE, Chen HSG, Moon TE, Young L, Surwit EA: Pharmacologic studies of anticancer drugs with the human tumor stem cell assay. Cancer Chemother Pharmacol 6:253–264, 1981.
Van Putten LM, Lelieveld P: The effects of cytostatic drugs and radiotherapy on the cell cycle. In: Scientific foundations of oncology, Symington T, Carter RL (eds.). William Heinemann Medical Books Ltd, London, pp 136–145, 1976.
Van Putten LM: Are cell kinetic data relevant for the design of tumour chemotherapy schedules? Cell Tissue Kinet 7:493–504, 1974.
Hill BT, Price LA: An experimental biological basis for increasing the therapeutic index of clinical cancer therapy. Ann NY Acad Sci 397:72–87, 1982.
Puck TT, Marcus PI: A rapid method for viable cell titration and clone production with HeLa cells in tissue culture: The use of X-irradiated cells to supply conditioning factors. Proc Natl Acad Sci USA 41:432–437, 1955.
Hamburger AW, Salmon SE: Primary bioassay of human tumor stem cells. Science 197:461–463, 1977.
Tveit KM, Endresen L, Rugstad HE, Fodstad Ø, Pihl A: Comparison of two soft-agar methods for assaying chemosensitivity of human tumours in vitro: Malignant melanomas. Br J Cancer 44:539–544, 1981.
Engelholm SAa, Spang-Thomsen M, Brünner N, Nøhr I, Roed H, Vindeløv L: In vitro culturing of tumor cells on soft agar. In: Human tumor cloning, Salmon SE, Trent JM (eds.), Grune & Stratton, New York, pp 197–203, 1984.
Hill BT, Whelan DH: Attempts to optimise colony-forming efficiencies using three different survival assays and a range of human tumour continuous cell lines. Cell Biol Int Rep 7:617–624, 1983.
Barnes D, Sato G: Methods for growth of cultured cells in serum-free medium. Analytical Biochem 102:255–270, 1980.
Carney DN, Bunn PA, Gazdar AF, Pagan JA, Minna JD: Selective growth in serum-free hormone-supplemented medium of tumor cells obtained by biopsy from patients with small cell carcinoma of the lung. Proc Natl Acad Sci USA 78:3185–3189, 1981.
Lechner JF, Haugen Aa, McClendon IA, Pettis EW: Clonal growth of normal adult human bronchial epithelial cells in a serum-free medium. In vitro 18:633–642, 1982.
Cowan DH, Graham J: Stimulation of human tumor colony formation by platelet lysate. J Lab Clin Med 102:973–986, 1983.
Engelholm SAa, Spang-Thomsen M, Vindelov LL: A short-term in vitro test for tumour sensitivity to adriamycin based on flow cytometric DNA analysis. Br J Cancer 47:497–502, 1983.
Meyskens FL, Thomson SP, Moon TE: Quantitation of the number of cells within tumor colonies in semisolid medium and their growth as oblate spheroids. Cancer Res 44:271–277,
Kressner BE, Morton RRA, Martens AE, Salmon SE, Von Hoff DD, Soehnlen B: Use of an image analysis system to count colonies in stem cell assays of human tumors. In: Cloning of human tumor stem cells. Salmon SE (ed.), Alan R Liss, New York, pp 179–193, 1980.
Salmon SE: Human tumor colony assay and chemosensitivty testing. Cancer Treat Rep 68:117–125, 1984.
Von Hoff DD: ‘Send this patient’s tumor for culture and sensitivity’. N Engl J Med 308:154–155, 1983.
Pettengill OS, Sorenson GD, Wurster-Hill DH, Curphey TJ, Noll WW, Cate CC, Maurer LH: Isolation and growth characteristics of continuous cell lines from small-cell carcinoma of the lung. Cancer 45:906–918, 1980.
Gazdar AF, Carney DN, Russell EK, Sims HL, Baylin SB, Bunn PA, Guccion JG, Minna JD: Establishment of continuous, clonable cultures of small-cell carcinoma of the lung which have amine precursor uptake and decarboxylation cell properties. Cancer Res 40:3502–3507, 1980.
Kolata G: Cell biology yields clues to lung cancer. Science 218:38–39, 1982.
Jiang TL, Liu RH, Salmon SE: Antitumor activity of didemnin B in the human tumor stem cell assay. Cancer Chemother Pharmacol 11:1–4, 1983.
Kisner DL, Mehta P, Paget GE, Von Hoff DD: Activity of Carbetimer in a human tumor cloning system. Investigational New Drugs 2:55–58, 1984.
Roed H, Vindeløv LL, Christensen IJ, Hansen HH, Spang-Thomsen M: Comparison of the potential of the 2 epipodophyllotoxin derivatives VP-16 and VM-26 on small cell cancer of the lung cell lines. Proc Am Assoc Cancer Res 26:1315, 1985.
Carney DN, Mitchell JB, Kinsella TJ: In vitro radiation and chemotherapy sensitivity of established cell lines of human small cell lung cancer and its large cell morphological variants. Cancer Res 43:2806–2811, 1983.
Wang-Peng J, Kao-Shun CS, Lee EC, Bunn PA, Carney DN, Gjazdar AF, Minna JD: A specific chromosome defect associated with human small cell lung cancer: deletion 3 p (14–23). Science 215:181–183, 1982.
Weisenthal LM: In vitro assays in preclinical antineoplastic drug screening. Semin Oncol 8:362–376, 1981.
Tveit KM, Fostad Ø, Pihl A: The usefulness of human tumor cell lines in the study of chemosensitivity. A study of malignant melanomas. Int J Cancer 28:403–408, 1981.
Anonymous: Testing anti-cancer drugs. Lancet 1972, i:827–828, 1972.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Martinus Nijhoff Publishers, Boston
About this chapter
Cite this chapter
Roed, H., Vindeløv, L.L., Spang-Thomsen, M., Engelholm, S.A. (1986). Limitations and Potentials of In Vitro Sensitivity Testing of Human Small Cell Carcinoma of the Lung. In: Hansen, H.H. (eds) Lung Cancer: Basic and Clinical Aspects. Cancer Treatment and Research, vol 28. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2295-5_5
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2295-5_5
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9414-6
Online ISBN: 978-1-4613-2295-5
eBook Packages: Springer Book Archive